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Background: The symptom burden associated with multiple myeloma (MM) is often severe. Presently, no instrument
comprehensively assesses disease-related and treatment-related symptoms in patients with MM. We sought to validate
a module of the M. D. Anderson Symptom Inventory (MDASI) developed specifically for patients with MM (MDASI-MM).
Methods: The MDASI-MM was developed with clinician input, cognitive debriefing, and literature review, and
administered to 132 patients undergoing induction chemotherapy or stem cell transplantation. We demonstrated the
MDASI-MM’s reliability (Cronbach α values); criterion validity (item and subscale correlations between the MDASI-MM
and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
and the EORTC MM module (QLQ-MY20)), and construct validity (differences between groups by performance status).
Ratings from transplant patients were examined to demonstrate the MDASI-MM’s sensitivity in detecting the acute
worsening of symptoms post-transplantation.
Results: The MDASI-MM demonstrated excellent correlations with subscales of the 2 EORTC instruments, strong ability
to distinguish clinically different patient groups, high sensitivity in detecting change in patients’ performance status,
and high reliability. Cognitive debriefing confirmed that the MDASI-MM encompasses the breadth of symptoms
relevant to patients with MM.
Conclusion: The MDASI-MM is a valid, reliable, comprehensive-yet-concise tool that is recommended as a uniform
symptom assessment instrument for patients with MM.
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Notwithstanding the use of novel agents [1] and treatment
advances such as autologous hematopoietic stem cell
transplantation (HSCT), multiple myeloma (MM) is often
associated with significant disease-related and/or
treatment-related side-effects [2-5]. Because toxicities from
induction therapy and HSCT are common [2-4], the symp-
tom burden associated with MM or its treatment (eg, bone
pain, fatigue, muscle weakness, nausea, vomiting, constipa-
tion, diarrhea) can be severe. Thus, effective symptom
management becomes a critical component of patient care.
Accurate symptom assessment in patients with MM
requires psychometrically validated tools that are clinically
efficient to administer. Instruments used previously (eg,* Correspondence: djones1@mdanderson.org
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reproduction in any medium, provided the orthe European Organization for Research and Treatment of
Cancer (EORTC) Quality of Life Questionnaire (QLQ-
C30) [6] and the EORTC Multiple Myeloma Module
(QLQ-MY20)) [7] include some symptom items but pri-
marily assess health-related quality of life (QOL). Further,
the QLQ-MY20 is administered in tandem with the QLQ-
C30 [7], resulting in a 50-item measure that can create
substantial patient burden. Other QOL instruments (eg,
the Functional Assessment of Cancer Therapy – Multiple
Myeloma) and scales assessing general cancer-related
symptoms (eg, the M. D. Anderson Symptom Inventory
(MDASI)) [8] have been used in patients with MM [9,10].
However, they do not capture the breadth of symptoms
unique to MM or its treatment.
To address this need, we developed a MDASI module
specifically for patients with MM. The MDASI is a reli-
able, valid instrument that was designed for ease oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(known as the “core” items) and 6 symptom-related inter-
ference items that are common across cancer types and
treatments [8]. A recent systematic review of symptom-
assessment instruments identified several advantages of
the MDASI compared with other measures [11]. The
MDASI is comprehensive yet brief, thus minimizing pa-
tient burden, and has a readily understood numeric scale
that can be adapted for telephone, electronic, or other
digital forms of administration. The developers of the ori-
ginal MDASI recognized that particular cancer types or
treatments may require the addition of specific symptom
items to the MDASI to ensure a comprehensive symptom
assessment [12]. These MDASI “modules” include the ori-
ginal MDASI’s 13 core symptom and interference items
augmented by additional symptom items specific to cer-
tain cancers or treatments. MDASI modules have been
developed and validated for patients with a variety of
cancers [12-15]. This study describes the psychometric




Data were derived from 2 studies in patients with MM
treated at The University of Texas MD Anderson Cancer
Center in Houston, Texas, between 2008 and 2011. The
first study assessed symptoms during induction therapy,
and the second, during HSCT. For the induction sample,
eligible patients had received ≤2 cycles of chemotherapy
and were scheduled for bortezomib or thalidomide.
Patients were assessed upon enrollment (baseline) and at
the end of induction to capture change in symptom
profiles in response to therapy. The transplant sample
was derived from patients undergoing autologous HSCT.
Patients were assessed before beginning high-dose
melphalan treatment (pre-HSCT) and at nadir of treat-
ment (7 days post-HSCT). Patients with relapsed or re-
fractory disease were not excluded from the study.
Additional inpatients [16] with MM were interviewed
for cognitive debriefing of the MDASI-MM.
All patients were 18 years of age or older, spoke Eng-
lish, and provided written informed consent. The studies
were approved by the MD Anderson Institutional Re-
view Board.
Data collection
Module development and cognitive debriefing
Symptom data was obtained via the MDASI-MM
(Additional file 1: Figure S1). The MDASI-MM was
developed using methods employed for previous MDASI
modules [14,15]. MM-related candidate items were
derived through patient report of symptoms to clinicians
via informal interviews, through clinician and researcherinput, and through an exhaustive literature search that
included a review of symptoms associated with both MM
and its treatment. The resulting MM-specific symptom
items were added to the original MDASI to form a
provisional MDASI-MM, which was then used for com-
prehensive patient interviews (cognitive debriefing) with a
sample of 20 inpatients with MM. Cognitive debriefing is
a critical component of instrument development during
which patients assess the relevance, comprehensibility,
and clarity of items. We asked patients whether the
MDASI-MM encompassed major symptoms of concern; if
the items presented were relevant and if any that seemed
important were missing; if the questions were easy to
understand; if any items seemed redundant; whether the
0–10 numeric scale was easy to use; whether patients were
comfortable answering the questions; and if they had
suggestions for making the questions more comfortable to
answer. The final MDASI-MM contains the MDASI’s 13
core symptom severity items and 6 interference items [8],
plus 7 MM-specific items (bone aches, muscle weakness,
sore mouth/throat, rash, difficulty concentrating, constipa-
tion, diarrhea). Patients rate symptoms on a 0–10 scale
ranging from “not present” to “as bad as you can imagine.”
Interference is rated on a 0–10 scale ranging from “did
not interfere” to “interfered completely.”
Scoring
MDASI-MM ratings can be used to derive 3 subscale
scores: mean core (13 MDASI core symptom items),
mean severity (13 MDASI core plus 7 MM-specific
items), and mean interference (6 interference items). The
interference items can be subdivided into mean activity-
related (interference with work, general activity, and
walking ability (WAW)) and mean mood-related (inter-
ference with relations with people, enjoyment of life, and
mood (REM)) dimensions [17]. Symptom severity can be
classified as 0 (none), 1–4 (mild), 5–6 (moderate), or
7–10 (severe) [17,18].
Criterion measures
EORTC QLQ-C30 and QLQ-MY20
The QLQ-C30 is a reliable, valid 30-item instrument
used to measure QOL in cancer patients [19]. The
QLQ-MY20 is a reliable, valid 20-item measure used in
combination with the QLQ-C30 to assess QOL in MM
patients [7]. Both consist of functional and symptom/
side-effect subscales and items. Higher functional
subscale scores represent higher levels of functioning,
whereas higher symptom/side-effect subscale and item
scores represent more-severe symptoms/side effects.
Eastern Cooperative Oncology Group performance status
Eastern Cooperative Oncology Group performance sta-
tus (ECOG PS) is used to estimate patients’ functional
Table 1 Demographic and clinical characteristics
Induction Transplant
(n = 64) (n = 68)
Patient characteristics, mean (SD)
Age, years 62.9 (11.98) 62.1 (7.42)
Education level, years 14.8 (2.20) 14.5 (2.18)
Patient characteristics, % (no.)
Sex
Men 59.4% (38) 69.1% (47)
Women 40.6% (26) 30.9% (21)
Race and ethnicity
White non-Hispanic 73.4% (47) 77.9% (53)
Hispanic 6.3% (4) 10.3% (7)
Black 12.5% (8) 10.3% (7)
Other 7.8% (5) 1.5% (1)
Baseline ECOG PS
Good (0–1) 82.8% (53) 95.5% (64)
Poor (2+) 17.2% (11) 4.5% (3)
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nosis [20]. ECOG PS is a reliable, valid 5-point measure
ranging from fully active (0) to deceased (5) [21,22].
Statistical analyses
Analyses were conducted using Statistical Package for
the Social Sciences version 17.0 (SPSS Inc., Chicago, IL).
Descriptive statistics were computed for symptoms and
subscales. Statistical significance was set at a 2-tailed α
level of .05.
Reliability
Internal consistency reliability of the MDASI-MM was
estimated by calculating Cronbach α values for the
MDASI-MM core, severity, interference subscales at base-
line (first MDASI-MM assessment). A Cronbach α value
≥0.70 indicates good internal consistency reliability [23].
Criterion validity
Criterion validity was examined by correlating selected
MDASI-MM items and subscales with those from the
QLQ-C30 and QLQ-MY20 at baseline. We hypothesized
that the MDASI-MM’s activity-related and mood-related
interference subscales would correlate with the physical-
function and emotional-function subscales, respectively,
of the QLQ-C30, and that the MDASI-MM’s symptom
subscales would correlate with the symptom/side-effect
subscales of the QLQ-MY20. Because the QLQ-MY20
disease-symptoms subscale contains primarily pain and
bone-ache-related items [7], we examined correlations of
the individual MDASI-MM “pain” and “bone aches”
items with this subscale.
Construct validity
Construct validity of the MDASI-MM was assessed by
evaluating its ability to distinguish between groups of
patients with clinical differences in ECOG PS (ie, good
(≤1) versus poor (≥2)) after induction or transplant.
Sensitivity
To evaluate the sensitivity of the MDASI-MM, we used
2 methods.
First, we assessed the MDASI-MM’s ability to detect
change in ECOG PS during the course of treatment. We
compared change in MDASI-MM ratings with change in
ECOG PS scores between 2 time points: either between the
first and last MDASI-MM assessments during induction
therapy or between pre-HSCT and 7 days post-HSCT.
ECOG PS was considered stable/improving if it remained
the same or decreased relative to baseline, and worsening if
it increased one or more points during treatment. Change
scores for the MDASI-MM subscales and individual items
were considered clinically meaningful at 0.5 standard devi-
ation (SD) or higher [24]. We anticipated that the stable/improving group would have no significant change in
MDASI-MM ratings but that the worsening group would;
therefore, we conducted 1-sample t-tests to examine
change in ratings for each MDASI-MM subscale.
Second, we examined the sensitivity of the MDASI-
MM to detect the acute worsening of the transplant
sample’s symptoms post-HSCT. We used paired t-tests
to examine change in scores for the MDASI-MM
subscales and individual items. Effect sizes were
calculated and an effect size >0.5 was considered clinic-
ally meaningful [25,26].
Results
Demographic and clinical characteristics of the samples
are summarized in Table 1. Mean age for the induction
sample (n = 64) was 62.9 years and for the transplant
sample (n = 68) was 62.1 years. Patients in both samples
were predominantly White non-Hispanic and had good
(0–1) baseline ECOG PS.
Validation of the MDASI-MM
Internal consistency reliability
The MDASI-MM subscales showed good reliability.
Cronbach coefficient α values were 0.85 for the core
subscale, 0.88 for the severity subscale, and 0.91 for the
interference subscale.
Criterion validity
The MDASI-MM’s severity subscale displayed good as-
sociation with the QLQ-C30 physical, role, cognitive, so-
cial, and emotional-functioning subscales (all P < .001)
(Table 2). As hypothesized, the MDASI-MM’s activity-
Table 2 Criterion validity: MDASI-MM subscales correlated with QLQ-C30 and QLQ-MY20 subscales (n = 55)
MDASI-MM QLQ-C30 QLQ-MY20
Physical function Role function Emotional function Cognitive function Social function Disease symptom Side effect
Core −0.43a −0.37a −0.60b −0.66b −0.41a 0.54b 0.67b
Severity −0.49b −0.44b −0.60b −0.69b −0.47b 0.60b 0.68b
Interference −0.70b −0.70b −0.51b −0.49b −0.64b 0.70b 0.49b
WAW −0.74b −0.72b −0.39a −0.43a −0.60b 0.70b 0.44b
REM −0.56b −0.57b −0.60b −0.50b −0.61b 0.60b 0.49b
a Significant at P < .05.
b Significant at P < .001.
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with the QLQ-C30 physical-function subscale, whereas
its mood-related-interference subscale correlated more
strongly with the emotional-function subscale (all P < .001).
MDASI-MM symptom subscales correlated well with the
disease-symptoms and side-effects subscales of the QLQ-
MY20 (all P < .001).
Individual MDASI-MM symptom items correlated
strongly with comparable items and relevant subscales
of the QLQ-C30 and QLQ-MY20 (Table 3). Strong
correlations existed for pain, fatigue, nausea, shortness
of breath, difficulty remembering, lack of appetite, dry
mouth, numbness, constipation, diarrhea, and bone
aches (all P < .001). Correlations between the MDASI-MM
pain and bone-aches items and the QLQ-MY20
disease-symptoms subscale were 0.71 and 0.69 (P <.001),
respectively.Table 3 Criterion validity: MDASI-MM items compared
with individual items or relevant subscales from the QLQ-
C30 and QLQ-MY20 (n = 55)
MDASI-MM individual
symptom items




Pain Q-9, 19 (QLQ C-30 pain subscale) 0.76c
Fatigue Q-10, 12, 18 (QLQ C-30 fatigue subscale) 0.75c
Nausea Q-14 0.77c
Shortness of breath Q-8 0.67c
Difficulty remembering Q-25 0.75c
Lack of appetite Q-13 0.66c




Bone aches Q-31 0.69c
a Numbered questions: Q-9: Have you had pain?; Q-19: Did pain interfere with
your daily activities?; Q-10: Did you need to rest?; Q-12: Have you felt weak?;
Q-18: Were you tired?; Q-14: Have you felt nauseated?; Q-8: Were you short of
breath?; Q-25: Have you had difficulty remembering things?; Q-13: Have you
lacked appetite?; Q-40: Have you had a dry mouth; Q-43: Did you have
tingling hands or feet?; Q-16: Have you been constipated?; Q-17: Have you
had diarrhea?; Q-31: Have you had bone aches or pain?
b Spearman’s correlations demonstrated similar magnitude as
Pearson’s correlations.
c Significant at P < .001.Construct (known-group) validity
Patients with good ECOG PS had significantly lower scores
for the MDASI-MM subscales than patients with poor
ECOG PS (all P < .001) (Table 4). Similar results were seen
for the MM-specific items (P < .001). Effect sizes for the
differences were ≥0.7, indicating medium to large effects.
Sensitivity to change in performance status
MDASI-MM subscale change scores were significant for
patients with worsening ECOG PS (core: t(65) = 8.350; se-
verity: t(65) = 8.672; interference: t(65) =7.344; all P < .001),
but were not significant for patients with stable/improving
ECOG PS. Difference scores between patients whose
ECOG PS worsened and patients for whom it remained
stable/improved were statistically significant for each
MDASI-MM subscale (all P < .001, all effect sizes ≥0.7)
(Table 5). Additionally, difference scores between the
groups were statistically significant for most individual
symptom items.
Sensitivity to impact of therapy (HSCT)
Substantial and statistically significant increases in
patients’ scores between pre-HSCT and 7 days post-
HSCT were observed, with effect sizes of 1.29, 1.33, and
0.95 for the core, severity, and interference subscales, re-
spectively (all P < .001) (Table 6). Differences in individ-
ual symptoms were also clinically significant for most
items, with effect sizes ≥0.5.
Cognitive debriefing
Cognitive debriefing interviews were conducted with 20
patients. All reported that they were comfortable
answering the MDASI-MM questions; that the question-
naire was easy to understand, and that it was compre-
hensive and non-repetitive. One patient reported
swelling/edema and night sweats. No other MM or
treatment-related symptoms were suggested during open
interviews.
Symptom severity
In order of severity, the most-severe symptoms reported
at induction baseline were fatigue, pain, disturbed sleep,
Table 4 Known-group validity: MDASI-MM symptom and interference subscale scores compared with ECOG PS scores
from final MDASI-MM assessment (n = 127)
MDASI-MM subscale ECOG PS No. of patients Mean SD Difference 95% CL Effect size
Lower Upper
Core Good 63 1.88 1.50 1.62a 1.50 2.26 0.89
Poor 64 3.50 1.79 3.06 3.95
Severity Good 63 1.72 1.38 1.43a 1.37 2.07 0.86
Poor 64 3.15 1.60 2.75 3.55
Interference Good 63 2.71 2.14 1.91a 2.17 3.25 0.75
Poor 64 4.62 2.57 3.98 5.26
a Significant at P < .001.
Jones et al. Journal of Hematology & Oncology 2013, 6:13 Page 5 of 9
http://www.jhoonline.org/content/6/1/13drowsiness, bone aches, dry mouth, and muscle weak-
ness; 35.9% of patients reported moderate to severe pain
(≥5 on the MDASI-MM) and 45.3% reported moderate
to severe fatigue [17]. At the end of induction, the most-
severe symptoms reported were fatigue, pain, muscleTable 5 Sensitivity of the MDASI-MM to change in ECOG PS (n
Stable/improving ECOG PS (n = 60)
Meana SD
Change in composite scores
Core subscale 0.07 1.54
Severity subscale 0.09 1.35
Interference subscale 0.16 2.63
Change in MDASI-MM items
Dry mouth −0.92 3.49
Fatigue −0.28 3.11





Mouth/throat sores 0.37 2.18
Pain −0.48 3.35
Muscle weakness 0.42 3.29
Numbness 0.90 2.70
Disturbed sleep 0.02 3.41
Bone aches −1.03 3.59
Shortness of breath −0.08 2.23
Sadness −0.02 2.00
Difficulty paying attention 0.25 1.87




a A positive mean indicates increased symptom intensity; negative indicates decrea
b Significant at P < .001.
c Significant at P < .05.weakness, disturbed sleep, drowsiness, numbness, and
bone aches; 27.4% of patients reported moderate to se-
vere pain and 30.6% reported moderate to severe fatigue.
The most-severe symptoms reported pre-HSCT were
fatigue, numbness, pain, disturbed sleep, bone aches,= 126)
Worsening ECOG PS (n = 66) Difference Effect size
Meana SD
1.66 1.62 1.59b 0.90
1.52 1.42 1.43b 0.91
2.15 2.38 1.99b 0.74
3.44 3.33 4.36b 1.08
2.44 2.68 2.72b 0.85
3.85 3.62 3.15b 0.85
3.48 3.60 2.80b 0.84
2.23 2.92 2.75b 0.74
3.68 3.67 2.53b 0.71
1.89 3.10 1.49c 0.59
1.86 3.41 1.49c 0.50
1.15 3.09 1.63c 0.49
1.83 2.52 1.41c 0.47
−0.24 2.21 −1.14c 0.45
1.20 3.21 1.18c 0.35
0.13 3.17 1.16c 0.34
0.68 2.23 0.76 0.34
0.55 2.77 0.57 0.23
0.65 2.12 0.40 0.20
0.27 1.62 0.25 0.15
−0.20 2.24 0.30 0.11
0.68 2.97 0.16 0.06
0.34 2.16 0.02 0.01
sed symptom intensity.
Table 6 Sensitivity of the MDASI-MM to impact of therapy: comparison of subscale and individual symptom scores pre-
HSCT and 7 days post-HSCT (n = 66)
Pre-HSCT Post-HSCT Differencea Effect size
Mean SD Mean SD
MDASI-MM subscales
Core 1.60 1.30 3.57 1.76 1.97b 1.29
Severity 1.43 1.14 3.21 1.62 1.78b 1.33
Interference 2.32 2.29 4.51 2.62 2.19b 0.95
Individual items
Lack of appetite 0.96 1.77 5.73 3.14 4.77b 1.43
Diarrhea 0.56 1.25 5.37 3.39 4.81b 1.36
Nausea 0.36 0.96 4.38 3.28 4.02b 1.20
Dry mouth 1.22 2.14 4.94 3.35 3.72b 1.11
Fatigue 2.99 2.52 5.86 2.40 2.87b 1.07
Drowsiness 1.88 2.12 4.53 2.56 2.65b 0.88
Mouth/throat sores 0.34 0.99 2.82 3.29 2.48b 0.81
Vomiting 0.06 0.29 2.29 3.16 2.23b 0.70
Muscle weakness 1.92 2.10 3.45 2.37 1.53b 0.56
Disturbed sleep 2.47 2.61 4.03 2.79 1.56b 0.49
Distress 1.82 2.41 3.03 2.91 1.21b 0.48
Pain 2.84 2.80 4.11 2.98 1.27c 0.44
Sadness 1.37 2.34 2.05 2.92 0.68c 0.30
Difficulty paying attention 1.06 1.57 1.57 2.01 0.51c 0.29
Shortness of breath 0.81 1.54 1.39 2.12 0.58c 0.25
Rash 0.38 1.33 0.88 2.00 0.50 0.21
Constipation 0.95 1.67 0.65 1.96 −0.30 0.20
Difficulty remembering 1.21 1.90 1.44 1.83 0.23 0.15
Numbness 2.90 3.00 2.70 2.99 −0.20 0.09
Bone aches 2.31 2.38 2.48 2.76 0.17 0.03
a Positive values indicate mean increase in symptoms post-HSCT; negative indicate mean symptom improvement.
b Significant at P < .001.
c Significant at P < .05.
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ate to severe pain, and 27.9% reported moderate to se-
vere fatigue. Post-HSCT scores reflected a signifi-
cant increase in symptom burden. The most-severe
symptoms reported post-HSCT were fatigue, lack of ap-
petite, diarrhea, dry mouth, drowsiness, nausea, and pain
(Figure 1).
MDASI-MM versus EORTC instruments
To examine how the top symptoms captured by the
MDASI-MM would compare with the top symptoms
captured by the QLQ C-30 and QLQ-MY20, we excluded
non-symptom items from the latter scales and compared
the top 5 symptoms identified by each instrument.
Although in different order of severity, 4 of the top 5
symptoms captured by the MDASI-MM (fatigue, pain,
disturbed sleep, drowsiness, bone aches) were identical tothose captured by the 2 EORTC instruments (bone aches,
fatigue, pain, disturbed sleep, and worry about health).
Discussion
This study evaluated an MM-specific module of the
MDASI in patients undergoing treatment for MM. Our
results provide strong psychometric evidence that the
MDASI-MM is a valid, reliable instrument that can dis-
criminate between clinically different patient groups and
that has high sensitivity in detecting symptom change
during treatment with respect both to patients’ ECOG
PS and evolving symptom trajectories. Individual items
and subscales of the MDASI-MM correlated strongly
with corresponding items and subscales of the EORTC
QLQ C-30 and QLQ MY-20. Cognitive debriefing
evidenced that the MDASI-MM is easy to understand,
quick to complete, and comprehensive.
Figure 1 Comparison of symptom severity for top 7 symptoms
during induction chemotherapy with their levels before and 7
days after hematopoietic stem cell transplant.
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brevity. For example, it captured 4 of the top 5
symptoms captured by the 2 EORTC instruments. Thus,
although brief, it captures patients’ most critical
symptoms with minimal patient burden. Additionally,
unlike the MDASI-MM, the 2 EORTC instruments are
QOL scales that were not developed within the concep-
tual framework of symptom assessment [7,19]. As the
QLQ C-30 must be administered with the QLQ MY-20
(a total of 50 items, compared with 26 items in the
MDASI-MM), this adds substantially to patient burden.
The MDASI-MM’s brevity also allows for efficient repeat
administrations for charting a patient’s symptom trajec-
tory over the course of treatment, which is a valuable aid
to clinical decision making. Previous research indicates
that patient-reported outcome measures can be effective
guides to key clinical decisions [27], especially when ob-
jective evaluations of physical indices are difficult [28].A significant advantage of MDASI modules is that
each module includes all symptom and interference
items from the original MDASI. Each module validation
subjects the original MDASI items to further cognitive
debriefing and sensitivity testing by additional patients,
reinforcing the validity, reliability, and sensitivity of the
original instrument. Original items can thus be included
in new modules with fewer psychometric steps, enabling
efficiency and cost savings in the development of
disease-specific modules. Also, because each new mod-
ule includes the original MDASI items, the use of
MDASI modules facilitates comparison of symptom
prevalence and severity across cancer types, a significant
benefit in clinical trials or studies that include patients
with different cancers.
During cognitive debriefing, 1 patient reported 2
symptoms not present in the MDASI-MM module
(swelling/edema and transient night sweats). These items
were not included in the final instrument as they
were extremely rare [16]. If these items are reported
in the literature with greater frequency, it may be
reasonable to include them in a future revision of the
MDASI-MM.
A limitation of our study was its largely racially
homogenous population; future work is needed to test
patients of diverse backgrounds in various treatment
settings. Another limitation is that although we were
able to demonstrate the sensitivity of the MDASI-MM
to change in performance status and to impact of ther-
apy, we were unable to demonstrate its sensitivity to
change in patients’ disease status (eg, stable or progres-
sive disease; partial or very good partial response) as
these data were not available. Our key strengths include
the development of an instrument based on symptom
burden rather than health-related QOL, and inclusion of
both induction and transplant patients, which extends
its generalizability.
Conclusions
Numerous clinical trials are underway for patients with
MM. Having a uniform, validated assessment instru-
ment to monitor disease-related and treatment-related
symptoms is therefore essential. Our study establishes
that the MDASI-MM is a reliable, valid instrument
developed with both patient and clinician input. Add-
itionally, due to its brevity, simple 0–10 assessment
scale, and ease of administration, it is a universally prac-
tical tool. The original MDASI is available in multiple
linguistically and psychometrically validated versions
[29-33], and MDASI modules such as the MDASI-MM
are readily translatable. We recommend the MDASI-
MM as a uniform symptom assessment instrument for
patients with MM in treatment settings and clinical
trials.
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